Phenotypes Associated with This Genotype

Genotype
MGI:5635880

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Tg(Pdx1-cre)6Tuv/0; Trp53^tm1Gev/Trp53^tm1Gev
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased pancreatic ductal adenocarcinoma incidence ( J:220300 )

• mice exhibit rapid development of pancreatic tumors within 8 weeks with features typical of human pancreatic adenocarcinoma

• tumors treated with ibrutinib show a reduction in proliferation rate and tumor fibrosis, inhibition of mast cell degranulation, and reduction in CD11b+ and F4/80+ macrophages and mice show increased survival

• mice treated with both ibrutinib and gemcitabine show extended survival compared to treatment with gemcitabine alone

• mice treated with a daily injection of cromolyn, a blocker of mast cell degranulation and inflammogen release, starting at 8 weeks of age show a reduction in F4/80+ cells and CD11b+ cells in the tumor stroma

endocrine/exocrine glands

increased pancreatic ductal adenocarcinoma incidence ( J:220300 )

• mice exhibit rapid development of pancreatic tumors within 8 weeks with features typical of human pancreatic adenocarcinoma

• tumors treated with ibrutinib show a reduction in proliferation rate and tumor fibrosis, inhibition of mast cell degranulation, and reduction in CD11b+ and F4/80+ macrophages and mice show increased survival

• mice treated with both ibrutinib and gemcitabine show extended survival compared to treatment with gemcitabine alone

• mice treated with a daily injection of cromolyn, a blocker of mast cell degranulation and inflammogen release, starting at 8 weeks of age show a reduction in F4/80+ cells and CD11b+ cells in the tumor stroma

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pancreatic carcinoma		DOID:4905	OMIM:260350	J:220300